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Hashimoto autoimmune thyroiditis (AIT) is the most common cause of acquired
hypothyroidism in the pediatric population. Development of AIT is mediated mainly by
cellular immune response directed toward thyroid autoantigens, leading to inflammation
and impaired function of thyroid gland. Both thyroid dysfunction and inflammation affect
the metabolism of plasma lipoproteins. The alterations in lipid profile worsen with the
advancement of hypothyroidism, ranging from discrete changes in euthyroid AIT patients,
to atherogenic dyslipidemia in the overt hypothyroidism. In this review, characteristics
of dyslipidemia in pediatric AIT patients, and the consequences in respect to the risk
for cardiovascular disease (CVD) development are discussed. Additionally, benefit of
L-thyroxine treatment on serum lipid profile in pediatric AIT patients is addressed.
Finally, potential usefulness of novel lipid biomarkers, such as proprotein convertase
subtilisin/kexin type 9 (PCSK9), non-cholesterol sterols, low-density lipoprotein particle
size and number, and high-density lipoprotein structure and functionality in AIT patients is
also covered. Further longitudinal studies are needed in order to elucidate the long-term
cardiovascular outcomes of dyslipidemia in pediatric patients with Hashimoto AIT.
Keywords: Hashimoto autoimmune thyroiditis, children, dyslipidemia, novel lipid biomarkers, L-thyroxine
treatment
INTRODUCTION
Hashimoto autoimmune thyroiditis (AIT) is the most common cause of acquired hypothyroidism
in childhood and adolescence. The prevalence of AIT in childhood peaks at early to mid- puberty.
Presentation of the disease is rare before the age of 3 years, but there are described cases in infancy,
too (1). Female strong preponderance has been reported with female to male ratio up to 3.4:1 (1–3),
with high prevalence in patients with Down and Turner syndrome (4). Clinical manifestations of
AIT in childhood are extremely diverse, ranging from completely normal, asymptomatic state, to
pronounced symptoms of severe thyroid dysfunction.
Thyroid hormones have a broad spectrum of physiological effects on lipoprotein metabolism.
As a result, plasma lipid and lipoprotein levels are sensitive to changes in the thyroid hormones
concentrations. The alterations in lipid profile accompanying AIT worsen along with the
advancement of hypothyroidism, ranging from discrete pro-atherogenic markers in euthyroid AIT,
to full-blown dyslipidemia in many patients with the overt hypothyroidism (5–7). Furthermore,
autoimmune disease itself has significant impact on lipid profile, as evidenced by a high prevalence
of dyslipidemia in patients with autoimmune diseases (8–10), which may account, at least in part,
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to the increased cardiovascular disease (CVD) risk. Thus, it could
be regarded as convenient that the efficacy of L-thyroxine (L-
T4) treatment in the normalization of lipid status is directly
proportionate to the degree of thyroid dysfunction, being
highest in the overt hypothyroidism (5, 7, 11, 12). However,
the waist majority of data linking autoimmune thyroid disease
with dyslipidemia were gained from the studies in adults (13),
whereas data in pediatric populations are limited. Also, data
is scarce regarding the effects of L-T4 treatment on lipid
profile in pediatric hypothyroidism, with or without thyroid
autoimmunity (14–18).
In this narrative review, we will discuss recent findings
regarding the effects of AIT on lipid metabolism and CVD
risk, including the impact of L-T4 treatment on dyslipidemia





Like other autoimmune diseases, AIT is multifactorial disease
caused by complex interplay of genetic (1, 19–26), environmental
(21, 27–29), and hormonal factors (19, 21, 30), that provoke
the inappropriate immune response against thyroid gland. HT is
mainly mediated by cellular immune response directed toward
thyroid autoantigens, leading to inflammation, fibrosis, and
impaired function of thyroid gland (4, 26). The first step in
pathogenesis is believed to be activation of autoreactive CD4+
T cells i.e., T helper (Th) cells specific for thyroid autoantigens.
Th cells type 1 (Th1) activate cytotoxic T lymphocytes (CD8+
lymphocytes) and macrophages, which directly destroy thyroid
follicular cells (31). Another subset of Th cells with a role in
development and progress of chronic inflammation and tissue
damage in HT are Th17 cells. Higher proportion of Th17 cells,
as well as higher levels of cytokines produced by these cells were
found in peripheral blood and thyroid tissue in HT patients
compared with healthy controls (32–34). It is also observed
that T regulatory (Treg) cells, cells with immunosuppressive
function, accumulate in thyroid tissue of HT patients. However,
in these patients Treg cells were found to be dysfunctional (35,
36). B lymphocytes, although representing humoral immunity,
are also activated in AIT, producing antibodies against thyroid
autoantigens (26). These cells are part of thyroid lymphocyte
infiltrate (37) and exert antibody synthesis in the gland (31, 38).
Autoantibodies are crucial component in AIT pathogenesis, since
antibody-dependent cell-mediated cytotoxicity is another and
important factor responsible for apoptosis of thyroid follicular
cells in this disease (26, 31).
Clinical presentation of AIT is best reviewed with respect
to the thyroid status, since children with AIT can present as
completely euthyroid, with mild subclinical hypothyroidism,
severe overt hypothyroidism, or in the state of subclinical or overt
hyperthyroidism (Hashitoxicosis) (39–43). Majority of children
with AIT are either euthyroid or subclinically hypothyroid at the
time of diagnosis (41, 42). Euthyroid state, defined by thyroid
function tests within normal range, is usually asymptomatic,
besides the frequent finding of a goiter (41, 42, 44, 45). Subclinical
hypothyroidism in AIT, defined by elevated TSH with normal
levels of serum thyroid hormones (fT4 and fT3), is usually
classified as mild (TSH 4.5–10 mIU/l) or severe (TSH > 10
mIU/l) (7, 41, 46–49). Although the very name—“subclinical
hypothyroidism” implies that this form of thyroid dysfunction
presents merely as a laboratory finding without any signs
or symptoms of clinical hypothyroidism besides goiter, these
patients actually may present with other clinical and laboratory
findings (7, 45, 47, 50, 51). Typical clinical signs and symptoms
of hypothyroidism have been reported in some children with
subclinical hypothyroidism, as well as the improvement of
hypothyroidism symptoms scores with L-T4 treatment (7, 47,
51). Also, untreated long-lasting subclinical hypothyroidism in
children has been firmly associated with subtle pro-atherogenic
alterations in lipid profile (7, 17, 52). On the other hand,
currently available data indicate that children with untreated
longstanding subclinical hypothyroidism have normal linear
growth, neurocognitive and behavioral outcomes, and bone
health status (7, 47, 48, 53). It should be noted that although
the association of obesity and subclinical hypothyroidism is well-
documented, abnormal thyroid function in obese patients seems
to be a consequence of obesity, rather than a cause (47, 48).
Overt hypothyroidism, defined by elevated TSH with low
level of serum fT4, is present in ∼20% of all children with
AIT at the time of diagnosis, and the onset of clinical
manifestations is usually subtle (41, 42, 46). Classical signs
and symptoms of overt hypothyroidism which may be seen in
these children are: goiter, constipation, weight gain, poor growth
velocity or short stature, fatigue and somnolence, poor school
performance, cold intolerance, dry skin, bradycardia, yellowish-
pale skin tone with facial puffiness (myxedema), with frequent
laboratory findings of anemia and dyslipidemia (41, 42, 46).
Adolescents with overt hypothyroidism can also present with
delayed or arrested pubertal development, irregular menstrual
periods, menometrorrhagia, or amenorrhea in girls (41, 46).
Rarely, girls with longstanding severe overt hypothyroidism can
present with precocious puberty and menstrual bleeding with
hyperprolactinaemia and delayed bone age (VanWyk-Grumbach
syndrome) (42, 46, 54).
Hashitoxicosis, the initial hyperthyroid phase of AIT
caused by the release of preformed thyroid hormones
from the gland, can be detected in ∼10%, and subclinical
hypothyroidism in up to 3% of children with AIT (39–
43, 55–57). Clinical signs and symptoms of children with
hashitoxicosis are those of hyperthyroidism, and cannot be
distinguishable can be indistinguishable from Grave’s disease:
goiter, tachycardia, tremor, weight loss, restlessness, warm
moist skin, ophthalmopathy, growth acceleration, delayed, or
precocious puberty (39, 41, 58). Fortunately, this hyperthyroid
phase of AIT is transient, usually resolving within several
months into euthyroid state, or progressing to permanent
hypothyroidism (41, 55, 56).
Apart from the described symptoms caused by the thyroid
dysfunction itself, children with AIT may also have other
autoimmune diseases or syndromes, such as celiac disease,
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type 1 diabetes (T1DM), Down’s or Turner’s syndrome,




In general, subclinical hypothyroidism can slow-down metabolic
pathways of cholesterol uptake, synthesis, and secretion, as
well as reverse cholesterol transport process and catabolism of
triglyceride (TG)-rich lipoproteins (Figure 1) (12, 59, 60). As
compared to healthy children, total and low-density lipoprotein
cholesterol (LDL-C) levels are commonly elevated, while the
level of high-density lipoprotein cholesterol (HDL-C) can be
normal or decreased in patients with subclinical hypothyroidism
(Table 1). Although some authors reported no differences in
serum lipid profile between pediatric patients with subclinical
hypothyroidism and controls, the frequency of dyslipidemic
children was significantly higher in the patients group (51,
61). The study evaluating children, adolescents and adults with
subclinical hypothyroidism suggested that abnormalities in lipid
profile are more pronounced in adult patients, as well as in those
with severe form of the disease (62). Yet, the impact of the disease
severity on lipid profile was not confirmed in later studies in
pediatric patients (61, 63).
The hallmark of subclinical hypothyroidism-related
dyslipidemia is reduced synthesis of liver LDL receptors
and the mechanisms behind this effect have been extensively
studied and explained. Emerging evidence suggests that the
levels of circulating proprotein convertase subtilisin/kexin type 9
(PCSK9), a serin-protease responsible for downregulation of liver
LDL receptors, is also increased in subclinical hypothyroidism
(64), paving the way for innovative lipid-lowering therapy in this
category of patients (5). However, data on PCSK9 in children are
FIGURE 1 | Main effector molecules involved in alterations of lipoprotein
metabolism driven by thyroid hormones. LDL, low-density lipoprotein; ABCA1,
ATP binding cassette subfamily A member 1; SR-BI, scavenger receptor class
B type 1; LPL, lipoprotein-lipase; HL, hepatic lipase; LCAT, lecithin:cholesterol
acyltransferase; CETP, cholesteryl-ester transfer protein.
sparse and the studies examining efficacy, safety, and tolerability
of PCSK9 inhibitors in pediatric patients are underway (65).
Body cholesterol pool is maintained by delicate balance
between the processes of cholesterol synthesis, absorption,
and biliary secretion, all of which can be affected even by
subtle alterations in thyroid hormones levels (60). Plasma non-
cholesterol sterols, including cholesterol precursors and plant
sterols, are validated biomarkers of cholesterol biosynthesis
and intestinal absorption efficiency (66). The results of a
small study by Matysik et al. (67) suggested that the levels
of plasma non-cholesterol sterols could serve as indicators of
disrupted cholesterol homeostasis in patients with hyper- and
hypothyroidism. Recently, plasma profile of non-cholesterol
sterols from birth to 15 years of age was characterized in pediatric
population without dyslipidemia (68). These data could form
a solid base for future evaluation of the extent of cholesterol
synthesis and absorption alterations in children and adolescents
with AIT.
The lack of thyroid hormones is associated with reduced
clearance of TG-rich particles, due to attenuated lipoprotein-
lipase (LPL) and hepatic lipase (HL) activities, and increased
production of very-low density lipoprotein (VLDL) particles
(5). Hence, apart from the impact on LDL-C level, thyroid
dysfunction may affect qualitative characteristics and functional
properties of LDL particles. Namely, hypertriglyceridemia is
intimately linked to the increased production of small, dense
LDL particles (69). Bearing in mind that thyroid hormones may
protect LDL particles from oxidation (70), and the fact that
small, dense LDL particles are prone to oxidative modifications
(69), there is increased potential for adverse modification of
LDL particles in hypothyroid state. Indeed, increased small,
dense LDL, and oxidized LDL particles were recently reported in
normolipidemic adult patients with hypothyroidism (71). These
data clearly demonstrated the usefulness of advanced lipid testing
for identification of the patients with high CVD risk, which
should be further confirmed in pediatric patients with both
subclinical and overt thyroid dysfunction.
In contrast to firm scientific and clinical evidence which
consistently points to elevated LDL-C concentrations in
patients with hypothyroidism, data regarding HDL-C are not
homogenous. As it has been presented in Table 1, HDL-C
levels were decreased or unchanged in hypothyroid states.
Interpretation of data and drawing of conclusions is particularly
complicated in pediatric population, since most of the data
regarding the association of HDL and thyroid status is derived
from studies in adults. It is also noteworthy that studies analyzing
HDL-C concentration in children with hypothyroidism were
conducted in smaller cohorts, which might affect the reliability
of the obtained results. Therefore, larger studies with prospective
design are needed to resolve this issue.
However, a contemporary approach to HDL’s clinical
significance might put aside these conflicting results concerning
HDL-C levels in hypothyroid subjects, since another question
is considered as even more important in modern research
and clinical practice. Namely, due to complex structure and
numerous functions of HDL, it is nowadays accepted that quality
of this lipoprotein’s particles is more significant than their
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TABLE 1 | Lipid profile of pediatric patients with subclinical hypothyroidism.
Authors N Age, years Alterations of lipid profile References
Paoli-Valeri et al. (2005) 17 4.3 ± 1.0 ↓HDL-C;↔TC;↔ LDL-C;↔ TG;↔ TC/HDL-C;↔ LDL-C/HDL-C (14)
Cerbone et al. (2014) 49 8.5 ± 0.5 ↓HDL-C; ↑TC/HDL-C; ↑TG/HDL-C;↔TC;↔ LDL-C;↔ TG;↔ non-HDL-C (17)
Dahl et al. (2018) 228 13.3 ± 4.2 ↑TC; ↑non-HDL-C;↔ HDL-C (18)
Catli et al. (2014) 27 10 (6.9)* ↔TC;↔LDL-C;↔HDL-C;↔TG (51)
Cerbone et al. (2016) 39 9.2 ± 3.6 ↓HDL-C; ↑TC-/HDL-C; ↑TG/HDL-C;↔TC;↔ TG;↔ LDL-C;↔ non-HDL-C (52)
Unal et al. (2017) 38 8.1 ± 3.6 ↑TC; ↑LDL-C; ↑LDL-C/HDL-C; ↑TC/HDL-C;↔ HDL-C;↔ TG (61)
Marwaha et al. (2011) 280/35# 12.8 ± 2.8 ↔/↓HDL-C;↔/↔TC;↔/↑ TG;↔/↑ LDL-C (62)
Isguven et al. (2016) 66 14.4 ± 2.4 ↑TC; ↑LDL-C;↔ TG;↔ HDL-C (63)
In relation to euthyroid or control group: ↑, increased; ↓, reduced;↔, unchanged. *Median (interquartile range) was reported. #280 patients with TSH≤ 10mIU/L and 35 patients with TSH
> 10 mIU/L were studied. TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides; non-HDL-C, non-high-density
lipoprotein cholesterol.
cholesterol content (72). As precisely summarized in a review
by Triolo et al. (73), functional properties of HDL could be
grouped in four essential categories: reverse cholesterol transport,
antioxidative, anti-inflammatory, and vasodilatatory activities. It
has also been demonstrated that alterations in HDL structure
affect its functionality. In addition, it is now clear that both
HDL structure and functions can be easily modified if changes
occur in their vascular environment (74). Therefore, several new
aspects should be considered regarding HDL in patients with
AIT, including the impact of subclinical or overt hypothyroidism
on HDL’s quality, as well as the influence of pro-inflammatory
and pro-oxidative environment on these particles. Providing
answers on these questions might have significant implications
for interpretation of CVD risk in AIT patients, especially those
of young age, considering their long-term exposure to possible
detrimental factors (Figure 2).
Changes of HDL’s structure and function in relation to
thyroid hormones status are largely unexplored. However,
a recent study has shown that both cholesterol eﬄux and
activity of HDL-associated enzyme paraoxonase 1 (PON1)
are decreased in patients with overt hypothyroidism (75),
thus implicating diminishing of HDL functionality. Several
reasons could be responsible for such findings. Namely, studies
involving human subjects and animal models have demonstrated
that hypothyroidism is associated with decreased activities of
cholesteryl-ester transfer protein (CETP), lecithin:cholesterol
acyltransferase (LCAT), and HL (76, 77). Having in mind that
these enzymes are key regulators of HDL metabolism, changes
in HDL structure and consequently function should be expected.
Indeed, a higher prevalence of larger HDL 2 subclasses was
found in subjects with hypothyroidism in a study by Tan
et al. (76). Larger HDL particles are generally considered as
highly atheroprotective, but, as it has been already mentioned,
novel data (75) suggest that functionality of HDL particles in
hypothyroidism is compromised.
The next aspect that should be considered is the impact
of inflammation on HDL particles. So far, changes in both
HDL-C level and HDL structure have been reported in several
autoimmune diseases (78). It is also noteworthy that AIT is the
most frequent co-morbidity of pediatric patients with T1DM
(79). In our recent study, we analyzed lipid and lipoprotein
subclasses profile in pediatric T1DM patients with and without
co-existing autoimmune diseases and found that those with
associatedHashimoto AIT hadmore profound dyslipidemia (80).
Generally speaking, HDL possesses strong anti-inflammatory
properties, but it has been demonstrated that pro-inflammatory
environment can diminish its protective capacity (78). Being an
autoimmune disease, Hashimoto thyroiditis is characterized by
chronic inflammation (81). Many components of inflammation
are shown to affect HDL particles. Previous researches pointed
toward serum amyloid A (SAA), which is abundantly produced
in inflammatory states and is capable to replace apolipoprotein
AI (apo-AI) on HDL particles, thereby diminishing their
anti-inflammatory properties and, paradoxically, turning them
into inflammatory agents (78). Moreover, it has been shown
that activity of LCAT is reduced (82) as a consequence of
inflammation and this can compromise maturation and normal
function of HDL particles. In addition, a decrease in CETP mass
and activity was also observed in pro-inflammatory conditions
(82, 83), although, it was suggested that this could be an adaptive
mechanism aimed to prevent massive HDL-C reduction, which
is driven by other factors (83). It should also be mentioned that
PON1 levels and activity are decreased during inflammation,
thereby diminishing antioxidative properties of HDL (84). As for
Hashimoto AIT, it has been shown that PON1 level is decreased
in these patients (85, 86).
Finally, HDL is a major carrier of sphingosine-1-phosphate
(S1P) and evidence suggests that the interaction of S1P with
HDL has significant impact on S1P activity (87, 88). S1P is well-
known mediator of immune response (89) and recently it has
been demonstrated that S1P participates in the development
of Hashimoto AIT through its interaction with S1P receptor
1 (90). Yet, whether structural changes of HDL participate
in modification of S1P activity in AIT is still to be revealed.
Furthermore, the impact of these interactions on increase of CVD
risk in Hashimoto AIT, especially in pediatric population, needs
to be evaluated.
Before making any conclusions regarding lipid status in AIT,
one should be aware that autoimmune disorders frequently
aggregate in the same patient. A recent review (91) has shown
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FIGURE 2 | Changes of HDL structure and functionality in Hashimoto thyroiditis. LCAT, lecithin:cholesterol acyltransferase; Apo-AI, apolipoprotein A-I; SAA, serum
amyloid A; PON1, paraoxonase 1; S1P, sphingosine-1-phosphate.
that various autoimmune comorbidities are associated with AIT
in an age-dependent manner. Namely, studies reported that
frequency of co-existing autoimmune diseases in children with
AIT ranges between 6.6 and 58.2%, wherein celiac disease and
T1DM are the most frequent comorbidities (91). Thus, possible
contribution of other co-existing autoimmune diseases on lipid
profile in AIT should not be neglected.
It is known that T1DM is associated with alterations of serum
lipid profile. Semova et al. (92) recently demonstrated decreased
cholesterol synthesis and increased cholesterol absorption, with
concomitant changes in TC, LDL-C, and HDL-C levels in young
patients with T1DM, when compared to age-matched healthy
individuals. Moreover, it has been suggested that both structural
and functional alterations affect HDL particles in T1DM (93).
Similarly, it has been shown that patients with celiac disease
exhibit changes in lipid profile, especially decreased HDL-C
concentration (94). Yet, it is noteworthy that independent effects
of co-existing autoimmune diseases on serum lipids are rarely
evaluated. However, it has been reported that LDL-C and TG
levels are higher in children with concomitant presence of T1DM
and celiac disease, when compared to children with T1DM alone
(95). Moreover, lower HDL-C levels were found in children
with T1DM if celiac disease was co-existing (96). Also, our
own results demonstrated that the prevalence of dyslipidemia
was higher in pediatric T1DM patients if celiac disease or AIT
were concomitantly present (80). Summarizing all mentioned
findings, eventual co-existence of other autoimmune diseases
should be taken into account for comprehensive evaluation
of dyslipidemia in AIT. Further studies are needed to fulfill
a gap in current understanding of mechanisms by which
polyautoimmunity is involved in development of lipid disorders.
EFFECTS OF L-THYROXINE TREATMENT
ON LIPID STATUS IN HASHIMOTO’S AIT
Most of the known data regarding the beneficial effects of L-T4
treatment on lipid profile is derived from studies in adults with
overt or subclinical hypothyroidism (12, 75, 97–102). Among
the recent studies, Minarikova et al. demonstrated significant
improvements of total cholesterol (TC), LDL-C, TG, apoB,
atherogenic index of plasma, and LDL subclasses following
L-T4 substitution treatment in 40 newly-diagnosed overt
hypothyroidism patients with AIT (103). Uniquely designed
study of 27 adult patients who underwent total thyroidectomy
and radioactive iodine treatment for differentiated thyroid
carcinoma, revealed that dynamic changes in thyroid function
are associated with corresponding dynamic changes of the
lipid profile and HDL function (75). Compared to the baseline
levels (on L-T4 treatment), when patients entered the overt
hypothyroid state (TSH > 30 mU/L after 4 weeks of L-
T4 withdrawal), the levels of TC, TG, LDL-C, apoA-I, and
apoB significantly increased, and then again recovered to the
baseline levels after 3 months, following the reinstitution of
L-T4 treatment. The levels of HDL-C increased during the
overt hypothyroid state, with impairment of function (evaluated
by cholesterol eﬄux capacity and PON1 activity), and these
changes persisted despite restoration of thyroid hormone levels.
It could not be concluded if impairedHDL-C function would also
improve after a longer period of follow-up (75).
Results from studies in the adult population also indicate that
L-T4 treatment could result in lowering of TPO-Ab levels in
patients with AIT (104, 105). This could also potentially lead to
the improvement of the lipid profile, having in mind that thyroid
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autoimmunity with higher TPO-Ab levels is associated with an
unfavorable lipid profile irrespective of thyroid function, in both
children and adults (13, 63, 80, 106, 107).
Subclinical hypothyroidism in children, with a prevalence
of 2–9%, is generally considered a benign condition with a
significant chance of remission, however, findings of subtle pro-
atherogenic abnormalities in these children highlights the lack of
consensus regarding treatment criteria (7, 17, 49, 52, 53, 108–
110). Treatment with L-T4, which was usually recommended
only in children with goiter, hypothyroidism symptoms or TSH
levels > 10 mU/L, is now being recommended by some experts
for treatment of mild subclinical hypothyroidism in cases of:
positive TPO-Ab, concomitant celiac disease, TSH > 8 mU/L
in two repeated measurements, gradually increasing TSH levels,
hyperlipidemia and younger patient age (7, 47, 49, 52, 53, 109).
Although the association of thyroid function with atherogenic
alterations in lipid profile has been well-documented in children,
data is scarce regarding the effects of L-T4 treatment in pediatric
hypothyroidism, with or without thyroid autoimmunity (14–18).
Dorr et al. observed a decrease of thyroid volume in 25 euthyroid
children with Hashimoto’s thyroiditis with L-T4 treatment, while
changes in lipids were not evaluated (44). Another study also
showed reduction of goiter with L-T4 treatment especially in
cases of overt hypothyroid, but also in SH and euthyroid children
with AIT (45).
Among the very few studies evaluating the effects of L-T4
treatment in children with subclinical hypothyroidism, only two
studies investigated changes in the lipid profile (51, 52, 108, 111,
112). In a prospective study by Catli et al., 27 children (median
age of 10 years) with subclinical hypothyroidism were treated
with L-T4 until achievement of euthyroid state plus 6 months
and then compared with euthyroid healthy control group. Seven
(26%) of these patients with SH had AIT. Although improvement
in the hypothyroidism symptoms score was associated with L-T4
treatment, no significant differences were observed regarding TC,
TG, HDL-C, and LDL-C (51). The absence of significant findings
could be attributed to the relatively short duration of follow-up
as well as low number of patients enrolled. On the other hand,
a prospective case-control study by Cerbone et al. discovered
significant effects of 2 years of L-T4 treatment on pro-atherogenic
markers in children with mild (TSH 4.5–10.0 mU/L) idiopathic
subclinical hypothyroidism (52). A total of 39 children (mean
age 9.2 years) with mild idiopathic subclinical hypothyroidism
were compared with healthy controls. However, in this study
patients with detectable TPO-Ab, Tg-Ab, or abnormal thyroid
echogenicity on ultrasound were excluded from the study. Mean
HDL-C levels were lower, with higher TG/HDL-C ratio and
atherogenic index (TC/HDL-C), in subclinical hypothyroidism
subjects compared with controls. After 2 years of L-T4 treatment,
these parameters improved significantly in the SH group, so no
more significant differences between subclinical hypothyroidism
subjects and controls were observed. It was concluded that 2
years of L-T4 treatment resulted in an improvement of many
lipid abnormalities in children with mild idiopathic subclinical
hypothyroidism (52). However, having inmind that patients with
AIT were excluded from this study, results should be interpreted
with caution in the context of pediatric hypothyroidism caused
by AIT. Further studies are needed to evaluate the metabolic
effects of L-T4 treatment in hypothyroid children with AIT,
compared with treated non-autoimmune hypothyroid children
and not treated healthy controls.
IMPLICATIONS FOR CARDIOVASCULAR
PREVENTION AND FUTURE DIRECTIONS
Dyslipidemia and increased carotid intima media thickness
(cIMT), a reliable indicator of subclinical atherosclerosis, was
recently documented in pediatric patients with Hashimoto
thyroiditis (61, 63), suggesting the importance of regular
evaluation of cardiovascular risk factors in children with AIT
(Figure 3). In recent years, the role of cholesterol in the
development of CVD has been challenged. In particular, the
main controversy was centered on the impact of dietary
fats on cardiovascular risk. According to a recent meta-
analysis by de Souza et al. (113), the intake of saturated fatty
acids was not associated with a higher cardiovascular risk.
Similarly, data from randomized controlled trials shows that
the replacement of saturated with polyunsaturated fatty acids
might reduce serum cholesterol levels, but does not decrease
the risk from all-cause or mortality due to coronary heart
disease (114, 115). Nevertheless, a panel of experts from the
European Atherosclerosis Society recently issued a Consensus
Statement, supported by the evidence from genetic, prospective
epidemiologic studies, Mendelian randomization studies and
randomized trials evaluating lipid-lowering therapies, that high
LDL-C is a causal factor in the pathophysiology of CVD and
should remain the main therapeutic target (116).
FIGURE 3 | The interplay between Hashimoto thyroiditis, dyslipidemia, and atherosclerosis.
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Although LDL-C level remains primary target for CVD
prevention, advanced lipid testing could be advised to reveal
hidden cardiovascular risk. In this context, lipoprotein particle
size, number and subclasses distribution, HDL lipidome,
proteome, and functionality testing may provide valuable
information beyond LDL and HDL cholesterol levels. Regarding
alterations in metabolism of TG-rich lipoproteins, it can be easily
assessed by calculation of non-HDL-C level, as it was recently
recommended by expert lipidologists (117). To date, increased
PCSK9 levels and its impact on dyslipidema has been reported
in the most common autoimmune disease in childhood, T1DM
(118), and future studies in pediatric Hashimoto thyroiditis
are warranted.
Another important aspect in addressing the link between
subclinical hypothyroidism and dyslipidemia is related to the
laboratory assessment and interpretation of TSH levels. As
stated previously, the definition of subclinical hypothyroidism
relies on a mildly elevated serum TSH concentration, which
is associated with normal T4 or fT4 levels. According to the
guidelines of European Thyroid Association for the management
of subclinical hypothyroidism in children, appropriate diagnosis
of subclinical hypothyroidism in pediatric patients requires
adequate age-adjusted reference ranges for TSH and thyroid
hormones is mandatory (119). To date, numerous studies have
been performed to define reference range of thyroid hormones
in pediatric population, and some of them stratified results
according to sex (120–122). Yet, there is still no consensus
regarding this issue. Onsesveren et al. (123) recently performed
a systematic review of published reference ranges for TSH
and fT4 in children and demonstrated substantial differences
among studies. For instance, the upper reference limit of TSH
ranged between 2.36 and 6.57 mU/L (123). The difference
among published reference values could be a consequence of age,
gender, and demographic characteristics of included populations,
including lifestyle, iodine, and selenium status (120) and/or
different assays employed for the laboratory measurements of
thyroid hormones. As previously acknowledged by the National
Academy of Clinical Biochemistry, serum TSH level has high
biological variability, due to short half-life and diurnal variation
(124). Also, as a consequence of improved sensitivity and
specificity of the methods for TSH determination, the upper
reference limit for TSH decreased over time. Finally, it should not
be neglected that thyroid hormones circulate bound to plasma
proteins, and their biological action is exerted by the fraction
(0.02–0.1%) of unbound or “free” form (4). Hence, the direct fT4
assays may be inaccurate in patients with severe systemic illness
or abnormalities of protein binding, so caution is needed when
interpreting such tests in this setting (4).
Unlike other forms of subclinical hypothyroidism in
childhood, Hashimoto AIT is characterized by an increased
likelihood for progression to overt hypothyroidism (47).
Long-term cardiovascular outcomes in pediatric patients with
Hashimoto thyroiditis are largely unknown due to lack of
longitudinal prospective studies. In addition, clinical studies
aimed to address benefit of L-T4 administration on future
cardiovascular health are required. Available data indicate
that statins also have certain immunomodulatory properties
(125). Hence, the impact on conventional dyslipidemia
treatment on thyroid autoimmunity should be explored in
the future.
CONCLUSIONS
Available evidence suggests that AIT is associated with profound
changes of lipid profile, which are driven not only by a
decrease in thyroid hormones, but also by chronic inflammation
and disturbed redox balance. In light of the current scientific
data, novel biomarkers of altered lipoprotein metabolism might
provide more complete information regarding lipid profile of
Hashimoto AIT patients and subsequent cardiovascular risk.
However, lack of reliable results in pediatric AIT patients urges
the need for more comprehensive studies aimed to explore
characteristics of dyslipidemia in children with Hashimoto AIT
and implications for their future cardiovascular health.
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